Patent ID: 8197826

Claim:
An immunomodulatory product obtained according to a method of preparation comprising the following steps: inoculation and incubation, under aerobic or anaerobic conditions and at a temperature of between approximately 30 to 40° C., of Bifidobacterium comprising at least the Bifidobacterium breve strain deposited under the number 1-2219 with the CNCM (Collection Nationale de Cultures de Microorganisms in Paris, France) in an aqueous substrate having a pH of between approximately 6 and 8 and comprising at least the following ingredients: i) lactoserum permeate, ii) a lactoserum protein hydrolyzate, iii) lactose, removal of the intact Bifidobacterium from the aqueous substrate; ultrafiltration of the aqueous substrate through filtration membranes having a cut-off threshold of between 100 and 300 kDa, so as to obtain a concentrated retentate; dehydration of the concentrated retentate; dissolution of the dehydrated retentate in a buffer; gel exclusion chromatography of the retentate solution, on a column having an exclusion threshold of 600 kDa; recovery of the excluded fraction at the end of the chromatography, which fraction constitutes the immunomodulatory product, and wherein the excluded fraction at the end of the chromatography is characterized by the absence of intact Bifidobacterium cells.